A controlled trial of lazabemide (RO19–6327) in untreated Parkinson's disease
Identifieur interne : 002566 ( Main/Exploration ); précédent : 002565; suivant : 002567A controlled trial of lazabemide (RO19–6327) in untreated Parkinson's disease
Auteurs : Karl Kieburtz [États-Unis]Source :
- Annals of Neurology [ 0364-5134 ] ; 1993-04.
Abstract
The monoamine oxidase type B inhibitor deprenyl (selegiline) has been demonstrated to delay the emergence of disability in early untreated Parkinson's disease. Lazabemide (RO19–6327) is a short‐acting, reversible, highly selective inhibitor of monoamine oxidase type B which, unlike deprenyl, is not metabolized to active compounds. We conducted a randomized, double‐blinded clinical trial to assess the short‐term tolerability of lazabemide in subjects who had early, untreated Parkinson's disease. Two hundred and one patients were enrolled at 14 centers and randomized to receive 100 mg/day, 200 mg/day, or 400 mg/day of lazabemide or matching placebo. Subjects were followed for 8 weeks including a randomized, double‐blinded withdrawal of lazabemide for 2 or 4 weeks. The primary measure of tolerability was the proportion of treated subjects who were able to complete the study on their originally assigned treatment. Clinical features were assessed by the Unified Parkinson's Disease Rating Scale (UPDRS). Lazabemide treatment was as well tolerated as placebo and was not attended by serious adverse experiences. A significant improvement in the activities of daily living component of the rating scale was found after 4 weeks of lazabemide treatment, although other subscale scores did not change significantly. The overall safety and benefits of lazabemide observed in this short‐term study justify further long‐term investigations to determine if this monoamine oxidase type B inhibitor can slow the clinical progression of Parkinson's disease.
Url:
DOI: 10.1002/ana.410330404
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A controlled trial of lazabemide (RO19–6327) in untreated Parkinson's disease</title><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:495F49F8EF5B8C19C3EAAA85532F06F532518680</idno><date when="1993" year="1993">1993</date><idno type="doi">10.1002/ana.410330404</idno><idno type="url">https://api.istex.fr/document/495F49F8EF5B8C19C3EAAA85532F06F532518680/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001359</idno><idno type="wicri:Area/Main/Curation">001151</idno><idno type="wicri:Area/Main/Exploration">002566</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A controlled trial of lazabemide (RO19–6327) in untreated Parkinson's disease</title><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Box 673, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1993-04">1993-04</date><biblScope unit="volume">33</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="350">350</biblScope><biblScope unit="page" to="356">356</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">495F49F8EF5B8C19C3EAAA85532F06F532518680</idno><idno type="DOI">10.1002/ana.410330404</idno><idno type="ArticleID">ANA410330404</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The monoamine oxidase type B inhibitor deprenyl (selegiline) has been demonstrated to delay the emergence of disability in early untreated Parkinson's disease. Lazabemide (RO19–6327) is a short‐acting, reversible, highly selective inhibitor of monoamine oxidase type B which, unlike deprenyl, is not metabolized to active compounds. We conducted a randomized, double‐blinded clinical trial to assess the short‐term tolerability of lazabemide in subjects who had early, untreated Parkinson's disease. Two hundred and one patients were enrolled at 14 centers and randomized to receive 100 mg/day, 200 mg/day, or 400 mg/day of lazabemide or matching placebo. Subjects were followed for 8 weeks including a randomized, double‐blinded withdrawal of lazabemide for 2 or 4 weeks. The primary measure of tolerability was the proportion of treated subjects who were able to complete the study on their originally assigned treatment. Clinical features were assessed by the Unified Parkinson's Disease Rating Scale (UPDRS). Lazabemide treatment was as well tolerated as placebo and was not attended by serious adverse experiences. A significant improvement in the activities of daily living component of the rating scale was found after 4 weeks of lazabemide treatment, although other subscale scores did not change significantly. The overall safety and benefits of lazabemide observed in this short‐term study justify further long‐term investigations to determine if this monoamine oxidase type B inhibitor can slow the clinical progression of Parkinson's disease.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002566 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002566 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:495F49F8EF5B8C19C3EAAA85532F06F532518680
|texte= A controlled trial of lazabemide (RO19–6327) in untreated Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |